Dr. Arun Chandavarkar retired as CEO & Joint Managing Director of Biocon Limited on 30 November 2019 after 29 years. Biocon, founded by Kiran Mazumdar-Shaw, is a leading Asian biopharma company focused on innovative, affordable treatments for chronic diseases like diabetes, cancer, and autoimmune conditions. Over three decades, Chandavarkar helped transform Biocon from an enzymes firm into a global biopharma player, contributing to its 2004 IPO, major biologics partnerships, R&D and infrastructure expansion, divestment of the enzymes business, and organizational restructuring. He holds a B.Tech from Indian Institute of Technology Bombay and a Ph.D. from Massachusetts Institute of Technology. He has served as Chairperson of the Biotechnology Committee at Confederation of Indian Industry and currently sits on the boards of Biocon Biologics and Mynvax.